“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP TAZ) Lotion in Patients With Baseline Body Surface Area of 6 -12%”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s37, https://doi.org/10.25251/skin.4.supp.37.